ES2604837T3 - Formulación de liberación sostenida que contiene anticuerpos para administración ocular - Google Patents

Formulación de liberación sostenida que contiene anticuerpos para administración ocular Download PDF

Info

Publication number
ES2604837T3
ES2604837T3 ES13705737.8T ES13705737T ES2604837T3 ES 2604837 T3 ES2604837 T3 ES 2604837T3 ES 13705737 T ES13705737 T ES 13705737T ES 2604837 T3 ES2604837 T3 ES 2604837T3
Authority
ES
Spain
Prior art keywords
sustained release
ocular administration
release formulation
formulation containing
containing antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13705737.8T
Other languages
English (en)
Inventor
John Grimshaw
Lutz Asmus
Michael Möller
Robert Gurny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech a Novartis Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech a Novartis Co LLC filed Critical Esbatech a Novartis Co LLC
Application granted granted Critical
Publication of ES2604837T3 publication Critical patent/ES2604837T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulación farmacéutica de liberación sostenida para administración ocular a un sujeto, que comprende un anticuerpo de cadena sencilla (scFv) y poli(ácido láctico) sustituido con hexilo (hexPLA).

Description

imagen1

Claims (1)

  1. imagen1
ES13705737.8T 2012-02-02 2013-01-31 Formulación de liberación sostenida que contiene anticuerpos para administración ocular Active ES2604837T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594099P 2012-02-02 2012-02-02
US201261594099P 2012-02-02
PCT/EP2013/051907 WO2013113820A1 (en) 2012-02-02 2013-01-31 Antibody-containing sustained-release formulation for ocular administration

Publications (1)

Publication Number Publication Date
ES2604837T3 true ES2604837T3 (es) 2017-03-09

Family

ID=47748581

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13705737.8T Active ES2604837T3 (es) 2012-02-02 2013-01-31 Formulación de liberación sostenida que contiene anticuerpos para administración ocular

Country Status (5)

Country Link
US (4) US20130202605A1 (es)
EP (1) EP2809344B1 (es)
JP (3) JP6184982B2 (es)
ES (1) ES2604837T3 (es)
WO (1) WO2013113820A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2604837T3 (es) 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular
WO2019217785A1 (en) 2018-05-10 2019-11-14 St. Jude Children's Research Hospital, Inc. High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro
GB202116442D0 (en) 2021-11-15 2021-12-29 Actome Gmbh High-efficacy labeling of antibodies with oligonucleotide labels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775778B2 (en) * 1999-01-05 2004-08-12 Flinders University Of South Australia, The Novel agents and methods for treatment and diagnosis of ocular disorders
US6773916B1 (en) * 1999-01-05 2004-08-10 The Flinders University Of South Australia Agents and methods for treatment and diagnosis of ocular disorders
AU2006223108A1 (en) * 2005-03-11 2006-09-21 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration
WO2007012979A2 (en) * 2005-04-22 2007-02-01 Universite De Geneve Polylactide compositions and uses thereof
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
CN106139123A (zh) * 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
ES2604837T3 (es) * 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular

Also Published As

Publication number Publication date
US20130202605A1 (en) 2013-08-08
US9873736B2 (en) 2018-01-23
EP2809344B1 (en) 2016-08-24
JP2015505551A (ja) 2015-02-23
JP2019081797A (ja) 2019-05-30
US10093726B2 (en) 2018-10-09
US20160362483A1 (en) 2016-12-15
JP6184982B2 (ja) 2017-08-23
JP2017165784A (ja) 2017-09-21
WO2013113820A1 (en) 2013-08-08
US20150044213A1 (en) 2015-02-12
EP2809344A1 (en) 2014-12-10
US20180362630A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CY1123515T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
MX2014009755A (es) Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
UY34705A (es) Películas de capas múltiples capaces de liberar ingredientes activos por un período limitado de tiempo
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
IN2015DN03984A (es)
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CO2017007316A2 (es) Formulación farmacéutica
AR092151A1 (es) Preparacion farmaceutica solida que contiene levotiroxina
MX353623B (es) Sistema de suministro de farmaco.
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201490862A1 (ru) Осмотически активная система вагинальной доставки
ES2604837T3 (es) Formulación de liberación sostenida que contiene anticuerpos para administración ocular
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης